Vogt P R, Brunner-La Rocca H P, Carrel T, von Segesser L K, Ruef C, Debatin J, Seifert B, Kiowski W, Turina M I
Clinic for Cardiovascular Surgery, the Divisions of Cardiology and Infectious Diseases, the Clinic for Radiology, and the Department of Biostatistics, ISPM, University Hospital Zurich, Switzerland.
J Thorac Cardiovasc Surg. 1998 Dec;116(6):965-72. doi: 10.1016/s0022-5223(98)70048-0.
Recent findings with cryopreserved heart valve allografts in the treatment of infectious endocarditis suggest that the use of cryopreserved arterial allografts may improve the outcome in patients with vascular infections.
Seventy-two patients with mycotic aneurysms (n = 29) or infected vascular prostheses (n = 43) of the thoracic (n = 26) or abdominal aorta (n = 46) were treated with in situ repair and extra-anatomic reconstruction using prosthetic material (n = 38) or implantation of a cryopreserved arterial allograft (n = 34). Disease-related survival and survival free of reoperation were assessed. Morbidity, cumulative lengths of intensive care, hospitalization, antibiotic treatment, and costs were calculated per year of follow-up.
The use of cryopreserved arterial allografts was superior to conventional surgery in terms of disease-related survival (P =.008), disease-related survival free of reoperation (P =.0001), duration of intensive care per year of follow-up (median 1 vs 11 days; range 1 to 42 vs 2 to 120 days; P =.001), hospitalization (14 vs 30 days; range 7 to 150 vs 15 to 240 days; P =.002), duration of postoperative antibiotic therapy (21 vs 40 days; range 21 to 90 vs 60 to 365 days; P =.002), incidence of complications (24% vs 63%; P =.005), and elimination of infection (91% vs 53%; P =.001). In addition, costs were 40% lower in the group treated by allografts (P =.005).
The use of cryopreserved arterial allografts is a more effective treatment for mycotic aneurysms and infected vascular prostheses than conventional surgical techniques.
近期关于冷冻保存的同种异体心脏瓣膜移植治疗感染性心内膜炎的研究结果表明,使用冷冻保存的动脉同种异体移植物可能改善血管感染患者的治疗效果。
72例患有真菌性动脉瘤(n = 29)或胸主动脉(n = 26)或腹主动脉(n = 46)感染性血管假体(n = 43)的患者接受了原位修复和使用假体材料(n = 38)或植入冷冻保存的动脉同种异体移植物(n = 34)的解剖外重建。评估疾病相关生存率和无再次手术生存率。计算每年随访的发病率、重症监护累计时长、住院时长、抗生素治疗时长及费用。
在疾病相关生存率(P = 0.008)、无再次手术的疾病相关生存率(P = 0.0001)、每年随访的重症监护时长(中位数1天对11天;范围1至42天对2至120天;P = 0.001)、住院时长(14天对30天;范围7至150天对15至240天;P = 0.002)、术后抗生素治疗时长(21天对40天;范围21至90天对60至365天;P = 0.002)、并发症发生率(24%对63%;P = 0.005)以及感染清除率(91%对53%;P = 0.001)方面,使用冷冻保存的动脉同种异体移植物优于传统手术。此外,同种异体移植物治疗组的费用低40%(P = 0.005)。
与传统手术技术相比,使用冷冻保存的动脉同种异体移植物治疗真菌性动脉瘤和感染性血管假体更有效。